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A B S T R A C T
Purpose: The study aim was to evaluate pharmacotherapy effects and long-term seizure outcomes in
patients with juvenile absence epilepsy (JAE) during a ﬁve-year follow-up period. The secondary aim was
to identify factors from patient history and determine their inﬂuence on seizure control.
Method: We retrospectively studied 46 patients with JAE in the period between 2006 and 2011. The age
at seizure onset, onset seizure type, family history of epilepsy, status epilepticus in history, medication
history, and the rate of seizure control were studied.
Results: There were 30 females (65.2%) and 16 males (34.8%) in the study. The mean age at seizure onset
was 12.9  5.6 years (ranged from 3 to 28 years). In 30 patients (65.2%), seizure onset was with absences, in
15 patients (32.6%) with generalized tonic-clonic seizure (GTCS), and in 1 patient (2.2%) with absence status.
In 43 patients (93.5%), GTCS occurred in the course of the disease. Family history for epilepsy was positive in
10 patients (21.7%). In the ﬁve-year follow-up period, seizure freedom (Group 1) was achieved in 7 patients
(15.2%). In total, 22 patients (47.8%) were classiﬁed into the groups involving very poor seizure control and
antiepileptic drug resistance (Groups 5 and 6). The mean number of antiepileptic drugs (AEDs) used in the
course of the disease in appropriate therapeutic doses was 3.8  2.3 (1–10 AEDs).
Conclusion: The study results show that almost half of JAE patients have poor seizure control with a high
rate of pharmacoresistance. The outcome of JAE can be very uncertain.
 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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According to ILAE Epilepsy Classiﬁcation (1989),1 juvenile
absence epilepsy (JAE) is classiﬁed among the age-related
idiopathic generalized epilepsies in adolescence. The proposed
ILAE Epilepsy Classiﬁcation revision2 gives preference to the terms
‘‘genetic’’ or ‘‘unknown’’ instead of ‘‘idiopathic’’. The presumablyAbbreviations: ESM, ethosuximide; GTCS, generalized tonic-clonic seizure; IGE,
idiopathic generalized epilepsy; ILAE, International League Against Epilepsy; JAE,
juvenile absence epilepsy; LEV, levetiracetam; LTG, lamotrigine; MRI, magnetic
resonance imaging; PRM, primidone; PSWC, polyspike-wave complex; SE, status
epilepticus; SWC, spike-wave complex; TPM, topiramate; VPA, valproic acid; ZNS,
zonisamide.
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St. Anne’s University Hospital and Faculty of Medicine, Masaryk University,
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1059-1311/ 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights regenetic cause and speciﬁc mutation in most patients with JAE is
still unknown. JAE is characterized by typical absence seizures, a
long-life prevalence of GTCS for 80–83% of patients,3,4 and sporadic
myoclonic jerks are observed in 20% of patients. The seizure onset
is typically between 9 and 13 years of age. GTCS and myoclonic
seizures often occur 1–10 years after the absence seizure onset.4
No sex predominance has been observed among the patients with
JAE.4 The incidence of JAE is not precisely known. JAE patients
account for approximately 2–3% of patients with adult epilepsy in
general, and about 8–10% of patients with idiopathic generalized
epilepsy (IGE).4 The etiology of JAE is a subject primarily of genetic
research. The research results have shown that genetic mutations
for voltage-gated sodium channels (CACNB4 gene)5,6 and potassi-
um channels (CLCN2 gene)5 are involved. Different mutations were
found in genes for GABA receptors (ligand ion channels),
speciﬁcally in the GABRA1 gene.7
The aim of this retrospective study is to evaluate the effects of
pharmacotherapy and the long-term seizure outcome in patients
with JAE in a tertiary referral center. To our knowledge, there is
insufﬁcient information concerning the long-term outcome ofserved.
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case history data (age at seizure onset, type of seizure at onset,
family history) and determine their inﬂuence on the rate of seizure
control.
2. Methods
We retrospectively evaluated the long-term seizure outcome in
patients with JAE who had been referred to the Epilepsy Center
Brno. We included only patients who had been observed and
clinically managed in the center for at least ﬁve years (speciﬁcally
in the period between 2006 and 2011). This period was described
as the observational period (OP).
All patients met the criteria of JAE according to the ILAE 1989
Classiﬁcation1 i.e. clinical (age at seizure onset, normal psycho-
motor development, presence of absence seizures, GTCS or non-
dominant myoclonic jerks) and electroencephalographic (normal
background activity, ictal pattern of bilateral, symmetric, and
synchronous discharge of regular 3–4 Hz spike wave discharges).
All patients underwent a 1.5 T MRI scan, which excluded patients
with potentially epileptogenic lesions.
We retrospectively evaluated the patient age at seizure onset,
seizure type, family history of epilepsy, status epilepticus in the
patient history, and history of medication, including the number of
AEDs and AED treatment during the OP. The rate of seizure control
was evaluated at the end of the ﬁve-year OP. The data concerning
the types of seizures and their frequency were based on interviews
with the patients and their caregivers. All of the patients were
regularly followed up during the whole OP for clinical purposes.
Patients from whom we could not obtain complete data or who
were assessed irregularly were excluded from the study.
According to the type of seizure control during the ﬁve-year OP
and at the end of the OP, we deﬁned the following outcome groups:
1. Completely seizure free
2. Only absence seizures
3. Only GTCSs with a frequency 1 seizure per yearFig. 1. Number of patients in different groups according to the 4. Only GTCSs with a frequency >1 seizure per year
5. Both GTCS and absence seizures; GTCSs with a frequency 1
seizure per year
6. Both GTCS and absence seizures; GTCSs with frequency >1
seizure per year
Since the data regarding the absence seizures were based on
interviews with patients and their caregivers, without video EEG
veriﬁcation, we did not precisely evaluate the frequency of this
type of seizure.
2.1. Statistics
We used the Mann–Whitney U-Test to analyze the possible
differences among patients who were or were not completely
seizure free during the whole OP in terms of their age, age at
epilepsy onset, and epilepsy duration. A chi-square test was used
to evaluate the possible differences among patients who were or
were not completely seizure free during the whole OP in terms of
the positive/negative family history and type of the seizure as a
ﬁrst manifestation of JAE (i.e. absences or GTCS). A value of p < 0.05
was considered statistically signiﬁcant.
3. Results
We studied a group of 46 patients (30 females and 16 males)
who met the criteria for JAE according to the ILAE 1989
Classiﬁcation1 and had been observed for at least 5 years. The
patient age ranged from 19 to 49 years with an average age of
31.2  8 years. There were 10 out of 46 patients (21.7%) with a positive
family history for epilepsy in our cohort. Because the evaluation was
retrospective, we were only able to obtain exact and speciﬁc data
concerning the type of epilepsy in each patients’ relative from 4 of the
10 patients. IGE (not more speciﬁed) was present in 2 patients’
relatives, 1 patient had a brother with febrile convulsions, and 1 patient
had a child with benign neonatal convulsions. Precise data concerning
the family history from other patients were not available.rate of seizure control at the end of the OP (pts: patients).
Table 1
AED treatment in the whole cohort of patients with JAE.
Treatment type AEDs No. of pts. Total no. of pts.




Combination of 2 AEDs VPA + LTG 5 20
VPA + LEV 4
LTG + LEV 3
TPM + ZNS 2
TPM + LTG 2
LTG + ZNS; LTG + ESM; CBZ + PRM; VPA + TPM Each 1
Combination of 3 AEDs VPA + PRM + LEV; VPA + LEV + ZNS; LEV + LTG + ZNS Each 1 3
Combination of 4 AEDs VPA + LEV + CBZ + CLN; VPA + LTG + PRM + CLN;
VPA + LTG + LEV + CLN
Each 1 3
No.: number; pts.: patients.
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manifestation was 12.9  5.6 years (ranged from 3 to 28 years). In
30 of the 46 patients (65.2%) the ﬁrst clinical manifestation of JAE
were absences, in 15 patients (32.6%) GTCS, and in 1 patient (2.2%)
absence status epilepticus. In 43 patients (93.5%), at least one GTCS
occurred in the course of the disease.
At the end of the OP, 7 of the 46 patients (15.2%) had been
seizure free during the whole OP (Group 1). In the same period,
8 patients (17.4%) had only absences (Group 2). Other types of
predeﬁned outcomes are presented in Fig. 1. In total, 31 patients
(67.4%) experienced at least 1 GTCS during the OP.
The assessment of AED treatment revealed that the number of
AEDs used in the history varied from 1 to 10 with an average of
3.8  2.3 AEDs. Only 8 of the 46 patients (17.4%) had just 1 AED,
19 patients (41.3%) had 3 or fewer AEDs, and 27 patients (58.7%) had
4 or more AEDs.
At the end of the OP, 20 of the 46 patients (43.5%) had been
treated by monotherapy, 20 patients (43.5%) used a combination of
2 AEDs concurrently, 3 patients (6.5%) used a combination of
3 AEDs, and 3 patients (6.5%) used a combination of 4 AEDs.
Patients from Group 1 (i.e. seizure-free patients during the
whole OP) were seizure free on 1 AED in 5 cases (71.4%) and on 2
AEDs in 2 cases (28.6%). In these patients, seizure freedom was
achieved by the use of 1 to 3 AEDs: 1 patient tried 1 AED, 4 patients
2 AEDs, and 2 patients 3 AEDs. Finally, 3 patients remains seizure-
free on monotherapy of LTG, 2 patients on monotherapy of VPA, 1
patient on the combination of VPA + LTG and 1 patient on the
combination of LTG + ESM.
The most commonly used AED in our series was lamotrigine (25
patients; 12 in monotherapy and 13 in combined therapy),
followed by valproic acid (20 patients; 5 in monotherapy and
15 in combined therapy) and levetiracetam (11 patients; all in
combined therapy). Other AEDs used both in monotherapy and in
combinations are noted in Table 1.
Statistical analysis did not reveal a statistically signiﬁcant
difference between the group of patients who were completely
seizure free during the whole OP (Group 1) and the patients who
were not (Groups 2–6) in terms of their age (p = 0.736), age at
epilepsy onset (p = 0.747), epilepsy duration (p = 0.666), positive/
negative family history (p = 0.557), or the type of seizure that was
the ﬁrst manifestation of JAE (0.854).
4. Discussion
Patients fulﬁlling the criteria for JAE according to the ILAE 1989
Classiﬁcation1 were enrolled in the study. The sub-classiﬁcation of
absence epilepsies in CAE and JAE is still a source of somecontroversy. We tried to exclude patients with CAE in terms of the
seizure onset (younger than 10 years) and the dominant type of
seizures (less often associated with other seizure types – GTCS and
myoclonic seizures). Patients with EEG characterized by polyspike
wave and wave complexes and dominant myoclonic seizures,
which ﬁt the diagnosis of JME, were also excluded from the study
even if they started with absences as a dominant seizure type at the
onset. Patients overlapping the boundaries between all the
syndromes, and who thus could not be assigned to one or another
group without effort and uncertainty, were excluded from the
study.
To our knowledge, there are not many studies concerning the
pharmacotherapy and long-term treatment outcome in patients
with JAE. This could be due to the relatively low prevalence of this
syndrome and the general opinion that JAE is classiﬁed as a
syndrome with a good prognosis and therapy responsiveness.
Literature data provide inconsistent results concerning the
long-term prognosis of patients with JAE. For example, Tovia et al.8
published a study of 17 patients with JAE with an average follow-
up period of 6.05 years (2–12 years). In the course of the follow-up
period, 8 of the 17 patients (43.7%) were seizure free. The average
disease duration was 6.93 years (1–13 years). The average patient
age when the remission of absences was observed was 15.75 years.
Eight of the 17 patients (47%) had GTCS in the course of the disease.
Trinka et al.9 published a study of 64 patients with JAE with an
average follow-up period of 25.8 years (3–69 years). Of the 64
patients, 40 patients (62%) were seizure free during the follow-up
for 2 or more years. Generally, seizure freedom can be achieved
with antiepileptic medication in 62–84% of all patients with
JAE.4,9,10
There are some studies that indicate that the outcome of
patients with JAE is not favorable as a rule. Wirell et al.11 studied
the prognostic factors of initial pharmacotherapy failure.
According to the study results, only 3 of the 11 children with
JAE (27.3%) were seizure free after the drug initiation (mostly
VPA).
There were 7 out of 46 patients (15.2%) seizure free (Group 1)
during the OP in this study. These patients did not achieve seizure
freedom after administration of 1 AED as we would expect. They
tried 1–3 AEDs and only 5 of them (10.9%) stayed on 1 AED during
the whole OP. Compared to the literature, Tovia et al.8 presented
nine of the 17 patients (52.9%) who were responsive for the ﬁrst
AED, but only 6 patients (35.3%) stayed seizure free on mono-
therapy during the follow-up period. These results show that even
in the group of patient who were seizure free, the seizure freedom
was not achieved in the simple way and does not have to be
permanent.
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worse prognosis. Only 37.5% of the patients in that study who
experienced GTCSs were seizure free during the follow-up period,
compared with 55.5% of patients without GTCSs. Similar results
were observed by Trinka et al.9 where the proportion of seizure
free patients in the follow-up period who experienced GTCSs was
35% compared to 78% of the patients with only absence seizures. In
this study, there was also a strong correlation between the mean
follow-up duration and outcome, indicating a lower proportion of
seizure-free patients with longer follow up periods. From this
point of view, the occurrence of GTCSs during the course of the
disease seems to be another important prognostic factor for the
long-term outcome in patients with JAE. In our study, only 8.7% of
the patients did not experience GTCS during the course of the
disease; therefore, we were unable to perform this type of
analysis.
The AEDs of choice in the JAE therapy are VPA and LTG. VPA is
the second medication choice for young women. Efﬁcacy was
also proved in ETS, LEV, TPM, and ZNS. VPA is an efﬁcient
treatment for all types of seizures in patients with JAE in 70–
80% of patients, LTG in 50–60% of patients.4,12 If VPA deals with
only partial seizure control, add-on LTG (GTCS) or ETS (absence
seizures) can be beneﬁcial.13 LEV can be efﬁcient in GTCS and
myoclonic seizures, and its efﬁcacy in absence seizures was
also recently proved.14–16 The ﬁrst AED in JAE therapy can be
efﬁcient in 60% of cases, especially in patients on VPA in
monotherapy or in patients with isolated absence seizures.
With monotherapy failure, the prognosis becomes less favor-
able and the rate of pharmacoresistance increases.11 The
results of this study concerning pharmacological treatment
show that patients used an average of almost 4 AEDs during the
course of the disease, and that 58.7% of patients tried more than
4 AEDs during the course of the disease from the seizure onset.
At the end of the follow up period, all of the patients were on
AED treatment: 43.5% were on monotherapy, 43.5% used a
combination of 2 AEDs, 6.5% used a combination of 3 or 4 AEDs.
LTG was studied in the paper published by Gericke et al.13 who
observed 12 patients with JAE on add-on therapy with
lamotrigine. The average follow-up was 25.5 months. Ten of
the 12 patients (83.3%) became seizure free on lamotrigine; in 2
of the 12 patients (16.6%) there was a seizure reduction of more
than 50% during the follow-up period.
Trinka et al. published a study of patients with CAE, JAE and
patients that could not be clearly deﬁned as either CAE or JAE,
and were therefore called ‘‘the overlap group’’. The follow-up
period was 25.8 years (range 3–69). 61 of the 81 patients (75%)
with nonpyknoleptic absences (JAE and ‘‘overlap group’’) were
on AEDs at the last follow-up visit. Of the 61 patients, 42
patients (69%) were on VPA monotherapy; 11 patients (18%)
were treated with VPA in combination with other AEDs (LTG,
ETS, PRM, TPM).
Our retrospective analysis of patients with JAE indicates that
more than half of the patients with this epileptic syndrome show
problems with seizure management and often require more AEDs
to reach partial or total seizure freedom. Although we did not
reveal a statistically signiﬁcant difference between the groups of
patients who were completely seizure free during the whole OP
and the patients who were not in terms of different variables, we
noticed that these patients became seizure free using less number
of AEDs. The number of studied patients did not allow us to
evaluate this difference statistically.
The results of this study have to be assessed in the context of
several facts:
 The study involves patients observed at a specialized center for
epilepsy. These are patients sent from outpatient clinics due totheir difﬁcult seizure management. The prognosis of these
patients is considered to be more grave.
 The study is retrospective. We were able to precisely assess the
frequency of GTCS, because their clinical manifestation is
noticeable. With absence seizures, patients do not often take
them into consideration and it is difﬁcult to count them exactly,
so we did not assess their frequency. Thus, we did not distinguish
between patients with rare absence seizures and daily absence
seizures. This could be quite misleading in the context of
assessing clinical manifestation.
 The assessment of patients was strictly set between 2006 and
2011. In this period of time, every patient presented in a different
phase of the disease.
5. Conclusion
The prognosis of patients with JAE is often unfavorable, and the
rate of pharmacoresistance can be quite important. To better
understand the course of the disease and its prognosis, more
studies are needed. We emphasize the need for studies with
longer follow-up periods that assess the rate of seizure manage-
ment and the cognitive and behavioral changes in patients with
JAE.
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